Puma Biotechnology Statistics
Share Statistics
Puma Biotechnology has 49.09M shares outstanding. The number of shares has increased by 1.83% in one year.
| Shares Outstanding | 49.09M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.08% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 34.92M |
| Failed to Deliver (FTD) Shares | 2.72K |
| FTD / Avg. Volume | 0.49% |
Short Selling Information
The latest short interest is 2.91M, so 5.92% of the outstanding shares have been sold short.
| Short Interest | 2.91M |
| Short % of Shares Out | 5.92% |
| Short % of Float | 8.34% |
| Short Ratio (days to cover) | 5.73 |
Valuation Ratios
The PE ratio is 9.45 and the forward PE ratio is 13.38. Puma Biotechnology 's PEG ratio is 0.22.
| PE Ratio | 9.45 |
| Forward PE | 13.38 |
| PS Ratio | 0.87 |
| Forward PS | 0.7 |
| PB Ratio | 3.82 |
| P/FCF Ratio | 14.2 |
| PEG Ratio | 0.22 |
Enterprise Valuation
Puma Biotechnology Inc. has an Enterprise Value (EV) of 231.00M.
| EV / Earnings | 10.7 |
| EV / Sales | 0.98 |
| EV / EBITDA | 4.86 |
| EV / EBIT | 7.08 |
| EV / FCF | 16.08 |
Financial Position
The company has a current ratio of 1.57, with a Debt / Equity ratio of 1.86.
| Current Ratio | 1.57 |
| Quick Ratio | 1.5 |
| Debt / Equity | 1.86 |
| Total Debt / Capitalization | 65.09 |
| Cash Flow / Debt | 0.27 |
| Interest Coverage | 2.45 |
Financial Efficiency
Return on equity (ROE) is 0.4% and return on capital (ROIC) is 18.84%.
| Return on Equity (ROE) | 0.4% |
| Return on Assets (ROA) | 0.09% |
| Return on Capital (ROIC) | 18.84% |
| Revenue Per Employee | 1.27M |
| Profits Per Employee | 116.71K |
| Employee Count | 185 |
| Asset Turnover | 1.02 |
| Inventory Turnover | 8.85 |
Taxes
| Income Tax | 1.08M |
| Effective Tax Rate | 0.05 |
Stock Price Statistics
The stock price has increased by -43.38% in the last 52 weeks. The beta is 1.08, so Puma Biotechnology 's price volatility has been higher than the market average.
| Beta | 1.08 |
| 52-Week Price Change | -43.38% |
| 50-Day Moving Average | 3.04 |
| 200-Day Moving Average | 3.44 |
| Relative Strength Index (RSI) | 49.17 |
| Average Volume (20 Days) | 555.19K |
Income Statement
In the last 12 months, Puma Biotechnology had revenue of 235.64M and earned 21.59M in profits. Earnings per share was 0.46.
| Revenue | 235.64M |
| Gross Profit | 172.96M |
| Operating Income | 32.64M |
| Net Income | 21.59M |
| EBITDA | 47.52M |
| EBIT | 32.64M |
| Earnings Per Share (EPS) | 0.46 |
Balance Sheet
The company has 84.58M in cash and 111.49M in debt, giving a net cash position of -26.91M.
| Cash & Cash Equivalents | 84.58M |
| Total Debt | 111.49M |
| Net Cash | -26.91M |
| Retained Earnings | -1.35B |
| Total Assets | 220.72M |
| Working Capital | 46.42M |
Cash Flow
In the last 12 months, operating cash flow was 27.01M and capital expenditures -12.64M, giving a free cash flow of 14.37M.
| Operating Cash Flow | 27.01M |
| Capital Expenditures | -12.64M |
| Free Cash Flow | 14.37M |
| FCF Per Share | 0.3 |
Margins
Gross margin is 73.4%, with operating and profit margins of 13.85% and 9.16%.
| Gross Margin | 73.4% |
| Operating Margin | 13.85% |
| Pretax Margin | 9.62% |
| Profit Margin | 9.16% |
| EBITDA Margin | 20.17% |
| EBIT Margin | 13.85% |
| FCF Margin | 6.1% |
Dividends & Yields
PBYI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 14.94% |
| FCF Yield | 9.49% |
Analyst Forecast
The average price target for PBYI is $7, which is 127.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 127.3% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | -5.97 |
| Piotroski F-Score | 5 |